Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407018 | 0.95 | HRH1 (0.49) | MEN1KMT2AADRB2HRH1CCR3 | |
| SCHEMBL4719968 | 0.89 | HRH1 (0.52) | MEN1KMT2AADRB2HRH1CCR3 | |
| SCHEMBL16982454 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2AHSD11B1ALDH1A1HPGD | |
| SCHEMBL18394775 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2AHSD11B1ALDH1A1HPGD | |
| SCHEMBL18407314 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2AHSD11B1ALDH1A1HPGD | |
| SCHEMBL15651538 | 0.78 | ALDH1A1 (0.57) | MEN1KMT2AHSD11B1ALDH1A1HPGD | |
| SCHEMBL5414999 | 0.76 | GPR119 (0.60) | MEN1KMT2AHRH1CCR3HRH3 | |
| SCHEMBL15652019 | 0.75 | HSD11B1 (0.52) | HSD11B1HPGD | |
| Acetic Acid SCHEMBL5407035 | 0.75 | HRH1 (0.66) | HRH1CCR3HSD11B1KCNH2 | |
| SCHEMBL21938860 | 0.74 | HSD11B1 (0.54) | MEN1KMT2AHSD11B1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | MEN1 696/4885KMT2A 3084/4885ADRB2 1158/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | MEN1 809/4885KMT2A 2792/4885ADRB2 969/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | MEN1 696/4885KMT2A 3084/4885ADRB2 1158/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | MEN1 696/4885KMT2A 3084/4885ADRB2 1158/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | MEN1 809/4885KMT2A 2792/4885ADRB2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.